Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TCR-like antibodies in cancer immunotherapy
Qinghua He, Zhaoyu Liu, Zhihua Liu, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
Delong Liu
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 87
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
Afsheen Raza, Maysaloun Merhi, Varghese Inchakalody, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 81
CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity
Madhura Modak, Ann-Kathrin Mattes, Daniela Reiss, et al.
JCI Insight (2022) Vol. 7, Iss. 11
Open Access | Times Cited: 62
Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
Xinbo Yang, Daisuke Nishimiya, Sara Löchte, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 7, pp. 932-943
Open Access | Times Cited: 35
TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
Mansour Poorebrahim, Niloufar Mohammadkhani, Reza Mahmoudi, et al.
Cancer Gene Therapy (2021) Vol. 28, Iss. 6, pp. 581-589
Open Access | Times Cited: 45
Challenges and solutions for therapeuticTCR‐based agents
Manish Malviya, Zita E. H. Aretz, Zaki Molvi, et al.
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 58-82
Closed Access | Times Cited: 16
Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
Paraskevi Vryza, Timo Fischer, Elena Mistakidi, et al.
Translational Oncology (2023) Vol. 38, pp. 101788-101788
Open Access | Times Cited: 15
Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies
Deepak Sherpally, Ashish Manne
Cancers (2025) Vol. 17, Iss. 4, pp. 589-589
Open Access
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs
Guo Shu-hua, Xiaozhi Xi
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process
Sara Feola, Jacopo Chiaro, Beatriz Martins, et al.
Cancers (2020) Vol. 12, Iss. 6, pp. 1660-1660
Open Access | Times Cited: 42
Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
Fenglong Bie, He Tian, Nan Sun, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 25
Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application
Ruihan Xu, Shiyao Du, Junmeng Zhu, et al.
Cancer Letters (2022) Vol. 546, pp. 215840-215840
Closed Access | Times Cited: 25
Antigen discovery for the development of cancer immunotherapy
Ryuhjin Ahn, Yufei Cui, Forest M. White
Seminars in Immunology (2023) Vol. 66, pp. 101733-101733
Open Access | Times Cited: 12
Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
Junjun Liu, Jianwei Zhu
International Immunopharmacology (2024) Vol. 138, pp. 112609-112609
Closed Access | Times Cited: 4
TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma
Mohamed S. Hussein, Qi Li, Rui Mao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
Luyao Wang, Zongxing Yang, Fucheng Guo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Computationally profiling peptide:MHC recognition by T-cell receptors and T-cell receptor-mimetic antibodies
Matthew I. J. Raybould, Daniel A. Nissley, Sandeep Kumar, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 9
Advances in plant-derived natural products for antitumor immunotherapy
Yi‐Hsin Yang, Qinying Liu, Xianai Shi, et al.
Archives of Pharmacal Research (2021) Vol. 44, Iss. 11, pp. 987-1011
Closed Access | Times Cited: 22
Novel strategies for immuno-oncology breakthroughs with cell therapy
Hongtao Liu, Chong-xian Pan, Wenru Song, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 20
TCR-like antibodies targeting autoantigen-mhc complexes: a mini-review
Ying Li, Wei Jiang, Elizabeth Mellins
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Immunotherapy: A new target for cancer cure (Review)
Fuqian Zhao, Dao-fu Shen, Mingquan Shang, et al.
Oncology Reports (2023) Vol. 49, Iss. 5
Open Access | Times Cited: 8
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
Hardik Mody, K. OGASAWARA, Xu Zhu, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 3, pp. 530-557
Closed Access | Times Cited: 8
The application of antibody-based agents in cancer therapy based on their mechanisms of action
Kewen Qian, Guangyao Li, Shuyi Zhang, et al.
Fundamental Research (2024)
Open Access | Times Cited: 2
Nanobody-based CAR T cells targeting intracellular tumor antigens
Haixia Li, Dani Zhong, Huiguan Luo, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113919-113919
Open Access | Times Cited: 12
The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy
Inbar Arman, Maya Haus‐Cohen, Yoram Reiter
Cells (2022) Vol. 12, Iss. 1, pp. 27-27
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top